Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: Brain Res. 2017 Dec 21;1702:85–95. doi: 10.1016/j.brainres.2017.12.029

Figure 1. Validation of the polyclonal SV2C antibodies with immunoblotting.

Figure 1

(A) Both the polyclonal human SV2C antibody (hSV2CpAb) and mouse SV2C antibody (mSV2CpAb) recognize human SV2C in transfected cell lines (HEK293 and PC12, neither of which endogenously express SV2C) and in endogenously-expressed mouse SV2C in mouse striatum homogenates and N2A cell lysates (B). Partial knockdown of endogenous SV2C using SV2C-targeted shRNA results in reduced immunoreactivity as compared to scrambled shRNA (“scram”) or control lysate with no shRNA transfection. The specific band is at the expected molecular weight of 90kD. Immunoreactivity at the specific band is eliminated in striatal homogenates from mice lacking SV2C (SV2C-KO). The unidentified nonspecific band at ~70kD remains in KO tissue and in untransfected cell lysate.